Another Disappointment For Pfizer; PAH Drug Withdrawn
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.
You may also be interested in...
Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning
REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.
Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning
REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.
“Fixer-Upper” Encysive’s Thelin Is Pfizer’s Problem Now
Pharma knight rescues Encysive, with its troubled Thelin for pulmonary hypertension, in a deal worth about $200 million.